Welcome to our dedicated page for Blade Air Mobility SEC filings (Ticker: BLDE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Strata Critical Medical, Inc., formerly Blade Air Mobility, Inc., files regulatory documents that document the company's transition from a broader air mobility platform to a critical medical business. The filings cover the completed Passenger business disposition, the corporate name change, Nasdaq-listed common stock under SRTA, and warrant-related capital-structure actions, including a Form 25 for removal of warrants from listing and registration.
Its 8-K reports and proxy materials disclose operating results from continuing operations, logistics and clinical revenue categories, material agreements, acquisition activity, credit arrangements involving operating subsidiaries such as Trinity Air Medical and Keystone Perfusion Services, and annual meeting governance matters. The record also includes exhibit filings, Inline XBRL cover data, and stockholder voting disclosures tied to the rebranded issuer.
Strata Critical Medical, Inc. investor Velibor Krstic filed a Schedule 13D after accumulating 764,435 public warrants to purchase Class A common stock. These warrants represent about 8.3% of the 9,166,644 public warrants outstanding, bought in Nasdaq open-market trades for roughly $15,231 of personal funds.
Krstic reports holding sole voting and dispositive power over all the warrants and states he acquired them for investment purposes, believing the SRTAW warrants are undervalued relative to the issuer’s fundamentals, including Adjusted EBITDA of $14.1 million and the integration of Keystone Perfusion. He indicates he may engage with the board, management, sponsor KSL Capital Partners, and other holders before the warrants’ May 7, 2026 expiration, potentially discussing actions such as a voluntary exchange offer or amendments to the Warrant Agreement.
Strata Critical Medical, Inc. Chief Accounting Officer Amir Cohen reported routine share dispositions related to tax withholding on vested restricted stock units. On September 4, 2025 and September 10, 2025, the issuer withheld a total of 9,190 shares of Class A common stock to satisfy tax obligations. After these withholdings, Cohen directly owns 94,570 shares. This amended filing corrects an earlier Form 4 that had overstated his direct beneficial ownership by 5,483 shares due to an omitted tax-withholding entry.
Wunsch Scott M reported acquisition or exercise transactions in this Form 4 filing.
Strata Critical Medical, Inc. CEO Scott M. Wunsch received an equity award of 18,067 restricted stock units tied to the company’s Class A common stock. The RSUs were granted at no cash cost to him as part of his quarterly commission program.
All 18,067 RSUs vest on June 8, 2026, provided he continues serving the company, and will be settled in shares upon vesting. After this grant, he holds 587,874 shares directly and 382,987 shares indirectly through a limited liability company of which he is the sole member.
Strata Critical Medical, Inc. reported a Form 4 for officer Scott M. Wunsch, CEO of Trinity Air Medical. On March 8, 2026, 3,631 shares of Class A common stock were withheld by the company to cover tax obligations from restricted stock unit vesting, a non-market disposition. After this, Wunsch held 569,807 shares directly and 382,987 shares indirectly through a limited liability company of which he is the sole member.
Strata Critical Medical, Inc. Chief Accounting Officer Amir Cohen reported a routine tax-withholding transaction. The issuer withheld 2,433 shares of Class A common stock at $4.54 per share to satisfy taxes on vested restricted stock units, and Cohen now directly holds 179,384 shares.
Strata Critical Medical, Inc. director and Co-CEO/General Counsel Melissa M. Tomkiel reported a routine tax-related share disposition. On March 8, 2026, 29,372 shares of Class A common stock were withheld at $4.54 per share to satisfy tax obligations from vesting restricted stock units. This was not an open-market sale but shares retained by the company to cover taxes. After this withholding, Tomkiel directly holds 1,613,990 shares of Class A common stock, indicating the transaction affected only a small portion of her overall position.
Strata Critical Medical, Inc. director and Co-CEO/CFO William A. Heyburn reported a tax-related share disposition. On March 8, 2026, 31,314 shares of Class A common stock were withheld by the company to satisfy tax obligations tied to vesting restricted stock units, rather than sold on the open market. After this withholding, Heyburn directly holds 1,336,774 shares of Class A common stock.
Strata Critical Medical, Inc., formerly Blade Air Mobility, describes its transformation into a focused provider of time‑critical logistics and clinical services for the U.S. transplant and broader healthcare markets. The company now operates two segments, Logistics and Clinical, offering air and ground organ transport, organ placement, surgical recovery, perfusion, preservation and cardiac care services under the Trinity and Keystone brands.
Strata highlights an asset‑light aviation model supplemented by a limited owned aircraft fleet, extensive use of third‑party operators, and proprietary technology to coordinate complex transplant workflows. In 2025 it divested its legacy Passenger business and acquired Keystone Perfusion Services, concentrating on Medical Customers such as transplant centers, hospitals and Organ Procurement Organizations.
The filing emphasizes numerous risks, including continued net losses, integration and divestiture execution, dependence on donor organ availability and reimbursement, operational and aviation safety hazards, climate and geopolitical disruptions, regulatory and privacy obligations, credit‑facility covenants, competition from integrated and device‑based rivals, and the need to recruit and retain specialized clinical, logistics and management talent.
Strata Critical Medical reported very strong growth for Q4 2025, with revenue rising 83.5% year over year to $66.8 million. Logistics revenue, which reflects organic growth, increased 35.3% to $49.2 million, while new Clinical operations contributed $17.6 million following the Keystone acquisition.
Gross profit nearly doubled to $14.4 million and gross margin improved to 21.6%. The net loss from continuing operations narrowed to $5.4 million, but the company remained unprofitable on a GAAP basis. Non-GAAP Adjusted EBITDA jumped to $7.0 million from $1.1 million.
For full year 2025, revenue reached $197.1 million and Adjusted EBITDA was $14.1 million, both above the high end of guidance. Strata raised its 2026 outlook to revenue of $260–275 million and Adjusted EBITDA of $29–33 million, and now expects free cash flow before aircraft and engine acquisitions of $15–22 million.
Cohen Amir reported acquisition or exercise transactions in this Form 4 filing.
Strata Critical Medical, Inc. Chief Accounting Officer Amir Cohen received an equity award in the form of 64,191 Restricted Stock Units (RSUs) of Class A common stock, reported at a price of $0.00 per share. After this grant, his directly held stake increased to 181,817 shares.
The RSUs will be settled in common shares as they vest. According to the vesting schedule, 6.25% of the RSUs (rounded down to the nearest whole number) will vest every three months after March 8, 2026, with any remaining unvested RSUs vesting on March 8, 2030, as long as he continues serving the company.